Phase I/Ib Pharmacokinetics Study of Oral MLN9708 Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients with Normal Renal Function or Severe Renal Impairment
ID Number 13-1476Principal Investigator(s)
Department(s) or Division(s)
Hematology and Medical Oncology
The purpose of this study is to assess the effect of MLN9708 on pharmacokinetics (which is how the body processes a drug) and safety in Multiple Myeloma patients with severe renal insufficiency versus those with normal renal function.
The use of MLN9708 in this study is experimental according to the FDA.
In Part A of this study, you will be treated with an investigational drug called MLN9708. MLN9708 is an experimental drug that is being developed as a possible treatment for cancer. In Part B of this study, you will be treated with MLN9708 in combination with dexamethasone. MLN9708 may also be called “study drug” in this document.
Recruiting Patients: No